Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) Short Interest Down 84.3% in June
by Amy Steele · The Cerbat GemMolecular Partners AG Sponsored ADR (NASDAQ:MOLN – Get Free Report) was the target of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 1,751 shares, a decline of 84.3% from the June 15th total of 11,177 shares. Based on an average daily trading volume, of 10,351 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the shares of the stock are sold short.
Hedge Funds Weigh In On Molecular Partners
A hedge fund recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new position in shares of Molecular Partners AG Sponsored ADR (NASDAQ:MOLN – Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is owned by institutional investors.
Analyst Upgrades and Downgrades
A number of brokerages have commented on MOLN. TD Cowen reissued a “buy” rating on shares of Molecular Partners in a report on Monday, March 16th. HC Wainwright reiterated a “buy” rating on shares of Molecular Partners in a research report on Monday, July 6th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Molecular Partners in a research note on Wednesday. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $8.38.
View Our Latest Report on MOLN
Molecular Partners Price Performance
Shares of MOLN stock traded up $0.03 on Friday, reaching $4.05. 2,345 shares of the stock were exchanged, compared to its average volume of 10,314. Molecular Partners has a one year low of $3.41 and a one year high of $5.36. The stock has a market cap of $163.58 million, a PE ratio of -2.09 and a beta of 1.08. The stock has a 50 day moving average price of $3.97 and a 200 day moving average price of $4.27.
Molecular Partners (NASDAQ:MOLN – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.45) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.02). On average, research analysts expect that Molecular Partners will post -1.28 earnings per share for the current fiscal year.
About Molecular Partners
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.
The company’s development pipeline spans infectious diseases, ophthalmology and oncology.